The fixed combination of propranolol and bendrofluazide in the treatment of hypertension.
The antihypertensive effect of Inderectic, a new combination capsule of propranolol 80 mg and bendrofluazide 2.5 mg, given twice daily was investigated in 21 hypertensive patients using a double-blind randomized crossover method. Inderectic was compared with either agent used alone and with the same combination given as separate tablets. It gave a greater fall in mean lying and standing systolic and diastolic blood pressure than either agent alone. There was no statistically significant difference for the effect on these variables between the free combination and combined formulation. Only minor side-effects were recorded, no patient having to be withdrawn from the study and no biochemical changes were observed.
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000008:administration & dosage / Q000627:therapeutic use*; D002214:Capsules; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*
D002214:Capsules; D004338:Drug Combinations; D001539:Bendroflumethiazide; D011433:Propranolol